Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
PYXS
Upturn stock ratingUpturn stock rating

Pyxis Oncology Inc (PYXS)

Upturn stock ratingUpturn stock rating
$1.1
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: PYXS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $6.2

1 Year Target Price $6.2

Analysts Price Target For last 52 week
$6.2Target price
Low$0.83
Current$1.1
high$5.39

Analysis of Past Performance

Type Stock
Historic Profit 110.98%
Avg. Invested days 22
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 68.14M USD
Price to earnings Ratio -
1Y Target Price 6.2
Price to earnings Ratio -
1Y Target Price 6.2
Volume (30-day avg) 7
Beta 1.18
52 Weeks Range 0.83 - 5.39
Updated Date 06/29/2025
52 Weeks Range 0.83 - 5.39
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.61

Earnings Date

Report Date 2025-06-11
When Before Market
Estimate -0.24
Actual -0.35

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -29.19%
Return on Equity (TTM) -66.31%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -16208616
Price to Sales(TTM) 4.11
Enterprise Value -16208616
Price to Sales(TTM) 4.11
Enterprise Value to Revenue 5.08
Enterprise Value to EBITDA 1.09
Shares Outstanding 61947700
Shares Floating 44649399
Shares Outstanding 61947700
Shares Floating 44649399
Percent Insiders 23.41
Percent Institutions 38.25

Analyst Ratings

Rating 3
Target Price 6.2
Buy 2
Strong Buy 4
Buy 2
Strong Buy 4
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Pyxis Oncology Inc

stock logo

Company Overview

overview logo History and Background

Pyxis Oncology Inc. is a clinical stage oncology company founded in 2019. It focuses on developing next-generation antibody-drug conjugates (ADCs) and immunotherapies to target difficult-to-treat cancers. The company went public in 2021.

business area logo Core Business Areas

  • Antibody-Drug Conjugates (ADCs): Developing novel ADCs targeting tumor-specific antigens. These ADCs are designed to deliver cytotoxic payloads directly to cancer cells, minimizing damage to healthy tissues.
  • Immunotherapies: Developing immunotherapies that enhance the body's immune system to fight cancer. This includes approaches such as bispecific antibodies and other immune-modulating therapies.

leadership logo Leadership and Structure

Lara S. Sullivan, M.D., is the President and CEO. The company has a board of directors overseeing strategic direction and a management team responsible for daily operations.

Top Products and Market Share

overview logo Key Offerings

  • PYX-106: PYX-106 is an anti-Siglec-15 antibody designed to block the activity of Siglec-15, an immunosuppressive protein expressed on tumor cells and certain immune cells. It is currently in Phase 1 clinical trials. Competitors include companies developing similar immunotherapies targeting immune checkpoints.
  • PYX-201: PYX-201 is an anti-EDB-fibronectin antibody-drug conjugate (ADC) designed to target tumors expressing EDB-fibronectin, an extracellular matrix protein enriched in the tumor microenvironment. It is in preclinical development. Competitors in this space are other companies working on ADCs, such as Seagen (SGEN) and Immunomedics (now part of Gilead, GILD).

Market Dynamics

industry overview logo Industry Overview

The oncology market is a large and rapidly growing market driven by increasing cancer incidence and advancements in treatment options, including targeted therapies and immunotherapies. There is significant competition and high unmet need.

Positioning

Pyxis Oncology is positioned as a company developing novel ADCs and immunotherapies targeting validated cancer targets. Its competitive advantage lies in its differentiated approach to ADC design and immunotherapy development.

Total Addressable Market (TAM)

The total addressable market for cancer therapies is estimated to be in the hundreds of billions of dollars. Pyxis Oncology aims to capture a portion of this market by developing differentiated therapies for specific cancer subtypes.

Upturn SWOT Analysis

Strengths

  • Novel ADC and immunotherapy platforms
  • Experienced management team
  • Focus on validated cancer targets
  • Strong intellectual property portfolio

Weaknesses

  • Early stage clinical development
  • Limited financial resources compared to larger pharmaceutical companies
  • Reliance on successful clinical trial outcomes

Opportunities

  • Positive clinical trial results could lead to partnerships or acquisitions
  • Expansion of pipeline through internal development or licensing
  • Address unmet needs in specific cancer subtypes

Threats

  • Clinical trial failures
  • Competition from other pharmaceutical companies
  • Regulatory hurdles
  • Patent challenges

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • MRK
  • BMY
  • AZN
  • LLY

Competitive Landscape

Pyxis Oncology is a smaller player in a competitive market. Its advantage lies in its innovative ADC and immunotherapy platforms, but it faces challenges from larger companies with more resources.

Growth Trajectory and Initiatives

Historical Growth: Due to Pyxis Oncology's relative youth as a company, historical growth is primarily reflected in its pipeline development and clinical trial progress.

Future Projections: Future growth depends on the successful completion of clinical trials and potential partnerships or acquisitions. Analyst estimates will vary.

Recent Initiatives: Initiating and advancing clinical trials for lead product candidates, expanding preclinical research programs, and exploring strategic partnerships.

Summary

Pyxis Oncology is a clinical-stage oncology company with a promising pipeline of ADCs and immunotherapies. Its success hinges on favorable clinical trial outcomes. A major risk is failure. The company operates in a highly competitive and regulated market. The company needs to secure more financing for operations.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports (estimates)
  • Industry publications

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market share estimates are approximations. Financial data may be outdated.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Pyxis Oncology Inc

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2021-10-08
CEO, President, Chief Medical Officer & Director Dr. Lara S. Sullivan M.D., MBA
Sector Healthcare
Industry Biotechnology
Full time employees 44
Full time employees 44

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.